(Q42799393)

7 November 2017

title

Tyrphostin AG 494 blocks Cdk2 activation (English)

1 reference

7 November 2017

Osherov N

1

1 reference

7 November 2017

Levitzki A

series ordinal

2

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

7 November 2017

1 reference

7 November 2017

volume

410

1 reference

7 November 2017

issue

2-3

1 reference

7 November 2017

page(s)

187-190

1 reference

Tyrphostins. II. Heterocyclic and .alpha.-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

Cell cycle checkpoints: preventing an identity crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

Signal-transduction therapy. A novel approach to disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2897%2900580-2

10.1016/S0014-5793(97)00580-2

7 January 2021

Identifiers

DOI

1 reference

7 November 2017

1 reference